Product Launch

Avacta Group Plc

Product Launch

ViVax Toolkitâ„¢ for structural analysis of vaccines

Avacta Group Plc ("Avacta" or the "Group") which provides advanced biophysics
technology and services to the biopharmaceutical, pharmaceutical, security, and
clinical diagnostic sectors, announces the launch of a new service for the
biopharmaceutical industry.

Avacta's ViVax Toolkitâ„¢ is designed to help companies foresee problems in the
drug development process before they arise and in doing so save time and money.
It utilises multiple biophysical techniques for the analysis of viral and other
types of vaccines, to assist in the development of new therapeutics, optimise
their manufacture and successfully navigate the regulatory process.

This has been developed to address a critical unmet need for detailed but rapid
analysis of complex biological entities, in response to requests from existing
clients and through consultation with others in the sector. Throughout the
process of bringing a vaccine to market, from the initial research stages
through to quality control checks of the end product, there is a strict
regulatory requirement for the characterisation of materials to ensure that the
final drug products are produced consistently.

The ViVax Toolkitâ„¢ will be delivered as an additional high value outsourcing
service and future revenues are expected to reflect the significant savings in
time and costs for customers in this high value sector through the provision of
cost effective and rapid biophysical techniques.

Prof. Alastair Smith, Avacta Group plc Chief Executive Officer, commented:

"We are confident that this new service, which builds upon existing
Avacta services, expertise and technology, will be readily adopted by
biopharmaceutical companies worldwide focused on developing the `well
characterized molecules' required by regulators.

"The ViVax Toolkitâ„¢ will provide viral, cancer and other types of vaccine
developers with a powerful and rapid method of characterising their materials
for regulatory approval, and is an important new service for the sector with
significant far-reaching opportunities."

                                                                4 April 2007

Enquiries

Avacta Group plc                          Tel: [phone]                 
                                                                             
Alastair Smith, Chief Executive                                              
                                                                             
Nexus Financial Ltd                       Tel: [phone]                 
                                                                             
Nicholas Nelson/Kathy Boate               [e-mail]